| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 05/04/2006 | US20060094751 Quinuclidine derivatives and pharmaceutical compositions containing the same |
| 05/04/2006 | US20060094746 poly(ADP-ribose) polymerase (PARP) inhibitors such as 9-hydroxythieno[2,3-c]isoquin-5(4H)-one, used for treating tumor diseases, leukaemia, sarcoma, tissue damage due to ischemia and reperfusion, inflammatory disease, retinal ischemia or brain trauma |
| 05/04/2006 | US20060094741 Remedies for neuropathic pain and model animals of neuropathic pain |
| 05/04/2006 | US20060094740 Polycyclic compounds as potent alpha2-adrenoceptor antagonists |
| 05/04/2006 | US20060094730 Water-soluble thalidomine derivatives |
| 05/04/2006 | US20060094729 metastatic or non-metastatic prostate cancer; for inducing apoptosis |
| 05/04/2006 | US20060094727 Inhibitors of macrophase migration inhibitory factor and methods for identifying the same |
| 05/04/2006 | US20060094725 N-heterocyclic derivatives as NOS inhibitors |
| 05/04/2006 | US20060094724 inhibitor of activated blood coagulation factor X; N-(5-chloropyridin-2-yl)-3- {[(trans-4-pyrrolidin-1 -ylcyclohexyl)carbonyl]aznino}furo[3,2-c]pyridine-2-carboxaxnide; disorders caused by thrombi and emboli in a mammal; decreased toxicity, and causes few side effects |
| 05/04/2006 | US20060094720 NK1 antagonists |
| 05/04/2006 | US20060094701 Respiratory system disorders; antiinflamamtory agents; side effect reduction; administering terbutaline |
| 05/04/2006 | US20060094691 Inclusion complexes of rosiglitazone |
| 05/04/2006 | US20060094685 Medicinal composition for drug-induced neuropathy |
| 05/04/2006 | US20060094037 Proteins related to schizophrenia and uses thereof |
| 05/04/2006 | US20060094013 Salt-inducible kinases 2 and use thereof |
| 05/04/2006 | US20060093671 Galantamine particles that may be in salt form and an excipient, coated by a release rate controlling membrane; alleviates Alzheimer's dementia and related dementias, when used in amounts insufficient to cause adverse effects |
| 05/04/2006 | US20060093665 Method to improve surface properties of pharmaceutical tablets |
| 05/04/2006 | US20060093612 Use of heat shock proteins to enhance efficacy of antibody therapeutics |
| 05/04/2006 | US20060093611 from mammalian chondrocyte progenitor cells expressing mechanosensitive TWIK-related potassium (TREK) ion channels; biocompatability, in vitro |
| 05/04/2006 | US20060093598 Stabilized liquid polypeptide-containing pharmaceutical compositions |
| 05/04/2006 | US20060093585 Providing mammalian cell contacted with agent and adeno-associated virus (AAV), identifying agent that when contacted with mammalian cell enhances AAV transduction after viral binding to membrane of contacted mammalian cell and before second strand synthesis which yields expressible form of viral genome |
| 05/04/2006 | US20060093579 Human recombinant beta-interferon with improved solubility |
| 05/04/2006 | US20060093576 Stabilized liquid polypeptide-containing pharmaceutical compositions |
| 05/04/2006 | US20060093574 Methods for epitope-specific and cytokine/anticytokine combination immunotherapies for modulation of pathogenic immune responses in immune mediated diseases |
| 05/04/2006 | DE102004052697A1 Pharmazeutische Zubereitungen zur Behandlung von Folgen des Alkoholmissbrauchs, Hepatitis, Pankreatitis, Alzheimererkrankung, Morbus Parkinson, Diabetes, toxischen Nierenerkrankungen, Reperfusionsschäden, der Arteriosklerose sowie als Antidote gegen Umweltgifte und Medikamentenintoxikation Pharmaceutical preparations for the treatment of episodes of alcohol abuse, hepatitis, pancreatitis, Alzheimer's disease, Parkinson's disease, diabetes, toxic kidney disease, reperfusion injury, atherosclerosis and as antidotes against environmental toxins and prescription drug intoxication |
| 05/04/2006 | DE102004052533A1 Particles for use in diagnosis and therapy, especially for binding therapeutic agent for treating e.g. tumors and bacterial, rheumatic, neurologic and thrombotic diseases, have nanocrystalline magnetic core and envelope enclosing core |
| 05/04/2006 | CA2730374A1 Compounds and compositions as inhibitors of cannabinoid receptor 1 activity |
| 05/04/2006 | CA2585418A1 4-aminotetracyclines and methods of use thereof |
| 05/04/2006 | CA2585248A1 Substituted tetracycline compounds |
| 05/04/2006 | CA2585014A1 Methylphenidate analogs and methods of use thereof |
| 05/04/2006 | CA2584986A1 Use of apoptosis inhibiting compounds in degenerative neurological disorders |
| 05/04/2006 | CA2584838A1 Novel diazabicyclic aryl derivatives and their medical use |
| 05/04/2006 | CA2584785A1 Compositions and methods for short interfering nucleic acid inhibition of nav1.8 |
| 05/04/2006 | CA2584775A1 Asymmetric synthesis of dihydrobenzofuran derivatives |
| 05/04/2006 | CA2584728A1 Asymmetric synthesis of substituted dihydrobenzofurans |
| 05/04/2006 | CA2584664A1 (biphenyl) carboxylic acids and derivatives thereof |
| 05/04/2006 | CA2584489A1 Kaspp (lrrke) gene, its production and use for the detection and treatment of neurodegenerative disorders |
| 05/04/2006 | CA2584241A1 Cgrp receptor antagonists |
| 05/04/2006 | CA2583550A1 Thienopyridines as allosteric potentiators of the m4 muscarinic receptor |
| 05/04/2006 | CA2580119A1 Amorphous object of cinnamide compound |
| 05/03/2006 | EP1652913A1 New strain of lactic acid bacterium and edible compositions, drugs and veterinary products containing it |
| 05/03/2006 | EP1652855A1 Polypeptides having brain disposition activity and utilization of the same |
| 05/03/2006 | EP1652848A1 Process for producing imide compound |
| 05/03/2006 | EP1652526A2 Use of (11beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatment of major depressive disorder |
| 05/03/2006 | EP1652518A1 Pharmaceutical composition for sublingual administration |
| 05/03/2006 | EP1652515A1 Process for producing drug ultramicroparticle and apparatus therefor |
| 05/03/2006 | EP1651632A1 Quinoline 4-carboxamide derivatives and their use as neurokinin 3 (nk-3) receptor antagonists |
| 05/03/2006 | EP1651622A1 Process for the preparation of 2- (quinoxalin-5-ylsulfonylamino) -benzamide compounds |
| 05/03/2006 | EP1651621A1 2- (quinoxalin-5-ylsulfonylamino) -benzamide compounds as cck2 modulators |
| 05/03/2006 | EP1651619A1 Substituted pyrimidin-4-ylamin analogues as vanilloid receptor ligands |
| 05/03/2006 | EP1651612A1 3,4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators |
| 05/03/2006 | EP1651342A2 Combinatorial synthesis on support |
| 05/03/2006 | EP1651250A1 Use of human growth hormone in multiple system atrophy |
| 05/03/2006 | EP1651243A2 Inhalable gaseous medicine based on xenon and nitrous oxide |
| 05/03/2006 | EP1651235A2 Sigma-1 receptor ligand with acetylcholinesterase inhibition properties |
| 05/03/2006 | EP1651232A2 Compounds for inflammation and immune-related uses |
| 05/03/2006 | EP1651223A1 2-methoxymethyl-3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]octane tartrate salts |
| 05/03/2006 | EP1651219A2 Aripiprazole and haloperidol pamoate salts |
| 05/03/2006 | EP1651169A2 Combination therapies for multiple sclerosis |
| 05/03/2006 | EP1651164A2 Composition and method for treating neurological disorders |
| 05/03/2006 | EP1560828B1 Imidazoquinoline derivatives as adenosine a3 receptor ligands |
| 05/03/2006 | EP1528923B1 N-((3-oxo-2,3-dihydro-1h-isoindol-1-yl)acetyl)guanidine derivatives as nhe1-inhibitors for the treatment of infarction and angina pectoris |
| 05/03/2006 | EP1513836B1 Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof |
| 05/03/2006 | EP1499611A4 Process for 5- 2(r)- 1(r)- 3,5-bis(trifluoromethyl)phenyl|ethoxy|-3(s)-(4-fluorophenyl)-4-morpholinyl|methyl|-1,2-dihydro-3h-1,2,4-triazol-3-one |
| 05/03/2006 | EP1499606B1 3, 4-dihydroquinolin-2(1h)-one compounds as nr2b receptor antagonists |
| 05/03/2006 | EP1467724B1 Orodispersible pharmaceutical composition comprising agomelatine |
| 05/03/2006 | EP1465870B1 Substituted 4-phenyltetrahydroisoquinolinium salts, method for production and use thereof as a medicament and medicaments comprising the same |
| 05/03/2006 | EP1444200B1 Azetidinyl diamines useful as ligands of the nociceptin receptor orl-1 |
| 05/03/2006 | EP1427724B1 Novel use of substituted aminomethyl chromans |
| 05/03/2006 | EP1368381B1 2-alkylated-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block |
| 05/03/2006 | EP1363618B1 Pharmaceutical composition for treating multiple sclerosis |
| 05/03/2006 | EP1355638B1 Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states |
| 05/03/2006 | EP1353904B9 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands |
| 05/03/2006 | EP1317273B1 Use of il-6r/il-6 chimera in huntington's disease |
| 05/03/2006 | EP1242400B1 Pyrrolidine derivatives as cyclic amp-specific phosphodiesterase inhibitors |
| 05/03/2006 | EP1232748B1 Use of substituted nitrobenzene derivatives for the treatment of diseases caused by bacteria, fungi and viruses |
| 05/03/2006 | EP1218023B8 Method for calming human beings using personal care compositions |
| 05/03/2006 | EP1212088B1 Use of anti rubeola antibodies for treatment of symptoms of central nervous system disorders |
| 05/03/2006 | EP1099692B1 N,n-substituted cyclic amine derivatives |
| 05/03/2006 | EP0937069B1 Piperazino derivatives as neurokinin antagonists |
| 05/03/2006 | EP0934326B1 Substituted aminoalkane phosphonic acids |
| 05/03/2006 | EP0804200B1 Use of noribogaine derivatives for treating chemical dependency in mammals |
| 05/03/2006 | EP0793500B1 Pharmaceutical compositions comprising nitric oxide-releasing polysaccharides |
| 05/03/2006 | CN1768065A Thienopyrimidine compound and use of the same |
| 05/03/2006 | CN1768061A Pyrazolo[1,5-a][1,3,5]triazine derivatives as cannabinoid receptor ligands |
| 05/03/2006 | CN1768058A Imidazopyridine derivatives as melanocortin receptor agonists. |
| 05/03/2006 | CN1768054A Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
| 05/03/2006 | CN1768053A Pyrazole compounds. |
| 05/03/2006 | CN1768051A Substituted pyrazoles |
| 05/03/2006 | CN1768043A 1,3,4-substituted pyrazoles for use as 5-ht receptor antagonists in the treatment of psychoses and neurological disorders. |
| 05/03/2006 | CN1768036A Indolone-acetamide derivatives, processes for preparing them and their uses |
| 05/03/2006 | CN1767870A Otorhinological delivery device |
| 05/03/2006 | CN1767834A Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders |
| 05/03/2006 | CN1767833A Use of carbamazepine derivatives for the treatment of agitation in dementia patients |
| 05/03/2006 | CN1767832A Combinations comprising anti-epileptic drugs for the treatment of neurological disorders. |
| 05/03/2006 | CN1767829A 4-(2-phenyloxyphenyl)-piperidine or -1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors. |
| 05/03/2006 | CN1765890A Modulators of dopamine neurotransmission |
| 05/03/2006 | CN1765416A Health caring plaster |
| 05/03/2006 | CN1765388A Quick-acting pain-alleviating broad-spectrum compound formulation |
| 05/03/2006 | CN1765379A Chinese herbal alcohol-neutralize healthy product and its preparation method |